Clinical Trials

47 enrolled 21 charts 1 FDA

Eosinophilia, Myeloproliferative Disorders

NCT00726232 2025-10-29

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

73 enrolled 25 charts

Myeloproliferative Disorders

NCT04182100 2025-09-15

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

29 enrolled 15 charts

Myeloproliferative Disorders, Polycythemia Vera

NCT04629508 2025-09-02

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

4 enrolled 10 charts

Phase 2 Active not recruiting

Myeloproliferative Disorders, Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT05482971 2025-08-13

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

91 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Thrombocythemia, Essential, Thrombocytosis

NCT04996875 2025-05-30

APEX

Phase 2 Recruiting

140 enrolled

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

NCT01761968 2025-04-30

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Phase 2 Active not recruiting

90 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

74 enrolled 40 charts

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

NCT04631211 2023-05-25

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Classical hematologyMyeloidOther hematologic neoplasm

21 enrolled

Anemia, Aplastic, Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Hematologic Neoplasms

NCT05612633 2022-11-10

AP-MPN

Phase 2 Withdrawn

Myeloproliferative Disorders

NCT03144687 2022-06-16

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

23 enrolled 31 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03287245 2021-12-08

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

27 enrolled 28 charts

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT03123588 2021-11-19

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

12 enrolled 15 charts

Myeloproliferative Disorders, Thrombocythemia, Essential

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

80 enrolled 31 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT01844765 2021-04-22

DIALOG

59 enrolled 33 charts 1 FDA

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myeloproliferative Disorders, Neoplastic Processes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00020969 2020-10-05

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT01998828 2020-04-20

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

39 enrolled

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis

NCT01348490 2020-01-28

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

66 enrolled 18 charts

Myeloproliferative Disorders

NCT01440374 2017-06-05

ASPIRE

Classical hematologyMyeloidOther hematologic neoplasm

162 enrolled 24 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT02125318 2017-02-27

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

MyeloidOther hematologic neoplasm

18 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT01340651 2014-03-10

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

41 enrolled 15 charts